Press Releases Archives | Page 81 of 116

I Peace’s GMP-grade iPSCs are key to manufacture Avery Therapeutics’ MyCardia™, a proprietary tissue-engineered heart graft developed to treat heart failure

December 16, 2020 By Cade Hildreth, Founder & President Leave a Comment

TUCSON, Ariz. and PALO ALTO, Calif., Dec. 16, 2020 — Avery Therapeutics, a Tucson-based company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, and I Peace, Inc., a Palo Alto-based biotech startup developing, mass-manufacturing, and commercializing Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs), announced a service agreement to advance cell therapy for heart failure. Under the agreement, I Peace will generate and supply GMP-grade induced pluripotent stem cells (iPSCs) and related services to Avery Therapeutics. Avery Therapeutics will use the iPSCs to derive cells used in the manufacturing of MyCardia™. [Read more…]

CILOA creates its new GMP-compliant production unit

December 16, 2020 By Cade Hildreth, Founder & President Leave a Comment

The French biotech company Ciloa creates its new GMP-compliant production unit as part of the development of a new generation of exosome-based vaccines and therapeutic vectors.

This first production unit is designed to meet GMP (Good Manufacturing Practices) standards, thereby ensuring the autonomy of Ciloa in the development of its biomanufacturing infrastructure and in the progress towards its future clinical studies.
The technology developed by Ciloa uses exosomes, small nanovesicles capable of transporting therapeutic proteins, for the development of a new generation of treatments and vaccines, notably in Covid-19 disease.

[Read more…]

Performance Cell Manufacturing, CDMO Division of VetStem Biopharma

December 8, 2020 By Cade Hildreth, Founder & President Leave a Comment

San Diego based Performance Cell Manufacturing is the newly formed CDMO division of VetStem Biopharma

Poway, California, December 8, 2020. – Performance Cell Manufacturing (PCM), is the newly formed contract development and manufacturing organization (CDMO) division of VetStem Biopharma.

PCM was born from VetStem’s 15 years of experience with cGMP compliant cell therapy product development and manufacturing. PCM provides cell therapy development and cGMP contract manufacturing for companies for FDA phase 1 and phase 2 clinical trials. [Read more…]

Sentien Biotechnologies Does First Subject with Ex Vivo MSC Therapy Against COVID-19

December 3, 2020 By Cade Hildreth, Founder & President Leave a Comment

Sentien Biotechnologies Does First Subject in a Phase 1/2 Trial of its Ex Vivo MSC Therapy Against Severe COVID-19 at the University of New Mexico Hospital.

LEXINGTON, MA, NOVEMBER 23, 2020 — Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that the first subject has been enrolled in its Phase 1/2 study of SBI-101 for the treatment of severe COVID-19 at the University of New Mexico (UNM) Hospital. SBI-101, Sentien’s innovative cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT). [Read more…]

The French Blood Agency announces agreement with TreeFrog Therapeutics to scale-up manufacturing of iPS-derived hematopoietic stem cell transplants

December 2, 2020 By Cade Hildreth, Founder & President Leave a Comment

TreeFrog Therapeutics will apply its proprietary technology for the mass-production of stem cell therapies to the world-first single-step protocol allowing the differentiation of human induced pluripotent stem cells (iPSCs) into fully functional human hematopoietic stem cells (HSCs). Resulting off-the-shelf universal HSC grafts could reduce costs and waiting times for patients in need of a bone marrow transplant.

Bordeaux, France – November, 17th, 2020 —The French Blood Agency (EFS) and TreeFrog Therapeutics announce a partnership to advance the mass-production of iPSC-derived HSC transplants based on a patented differentiation protocol developed by the EFS (UMR S938), the Institute for Radioprotection and Nuclear Safety (IRSN) and Sorbonne University [1]. [Read more…]

The French biotech company Ciloa creates its new GMP-compliant production unit as part of the development of a new generation of exosome-based vaccines and therapeutic vectors.

This first production unit is designed to meet GMP (Good Manufacturing Practices) standards, thereby ensuring the autonomy of Ciloa in the development of its biomanufacturing infrastructure and in the progress towards its future clinical studies.

The technology developed by Ciloa uses exosomes, small nanovesicles capable of transporting therapeutic proteins, for the development of a new generation of treatments and vaccines, notably in Covid-19 disease.

San Diego based Performance Cell Manufacturing is the newly formed CDMO division of VetStem Biopharma

Sentien Biotechnologies Does First Subject in a Phase 1/2 Trial of its Ex Vivo MSC Therapy Against Severe COVID-19 at the University of New Mexico Hospital.